Comments Regarding Quantitative Labeling of Sodium, Potassium, and Phosphorus for OTC and Prescription Drug Products Share page: Docket Number: FDA-2021-D-0528 Download Document Issues: OTC Medicines Other Issues Labeling Quality Related Posts Letter Letter Regarding Office of Management & Budget Request for Information: Deregulation May 12, 2025 Press Releases and Statements Veteran Scientist & Regulator Joins CHPA’s Senior Management Team May 12, 2025 Press Releases and Statements CHPA Submits Official Comments on Section 232 National Security Investigation of Pharmaceuticals May 8, 2025